Despite AstraZeneca-Daiichi Sankyo’s oncology drug, Dato-DXd, posting positive high-level phase III results, the markets doubted whether 1/ the efficacy was ‘clinically meaningful’, and 2/ the drug had safety issues. Yesterday’s 8% drop in the Astra share price was clearly an over-reaction as it is too early to draw unfavourable conclusions considering Dato-DXd’s six ongoing phase III trials. Therefore, the correction, in conjunction with the fact that Astra’s shares have lagged Big Pharma ytd, ....
